Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eloxatine Progression-Free Survival Data Not Enough For Colorectal Use

Executive Summary

Studies showing an overall survival advantage for Sanofi-Synthelabo's Eloxatine over 5-FU-based chemotherapy would be needed for approval of the agent as first-line therapy for colorectal cancer, FDA's Oncologic Drugs Advisory Committee found March 16.

You may also be interested in...



FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop

Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints

FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop

Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints

Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003

Sanofi-Synthelabo Eloxatin first-line data in advanced colonic and rectal adenocarcinoma will be submitted to FDA by the third quarter of 2003, following oxaliplatin's approval as second-line use

Related Content

UsernamePublicRestriction

Register

PS035755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel